Research Print E-mail

Dr Tingate established a number of lasting research partnerships between Australian and United States Universities, including the Life sciences Division of NASA. His research findings remain fundamentally important to a successful manned mission to Mars.

 

 

Research interests

 

TNF (tumor necrosis factor)

Vaccine development

Inflammation

Diseases of aging

 

Dr Tingate has consulted for a number of major Medical Research organisations helping to develop new immune therapies for diseases such as rheumatoid arthritis, crohn's disease, psoriasis and Alzheimer's disease. As Executive Medical Director of  Amgen Inc, he helped to develop many of the biotechnology products that will change the way we treat diseases this century.

 

 

 

 

Additional areas of research:

 

1.        Use of antibiotics for acute exacerbations of CLD in a community setting in Australia (Observational study)

2.       TNF blockers for the treatment of Rheumatoid arthritis (Phase 2-4 studies, health economics submissions)

3.        TNF blockers for the treatment of psoriasis (Phase 2-3 studies)

4.       PDF-5 inhibition for the treatment of erectile dysfunction (Phase 2-3 studies)

5.        Weight loss drugs in the setting of type 2 diabetes (Phase 4 study)

6.       Activated protein c for the treatment of meningococcal sepsis (Phase 4 study)

7.        Levosimendan, calcium channel sensitizer, for the treatment of severe heart failure (Phase 2 study)

8.       RANK ligand inhibition in osteoporosis (Phase 3 study)

9.       Increasing the sensitivity of the calcium-sensing receptor in the treatment of secondary hyperparathyroidism of CRF (Phase 4 study)

 

 

 

 
Last Updated ( Wednesday, 26 May 2010 17:39 )